Real-World data dive: does lung cancer treatment work equally for all?
NCT ID NCT06269133
First seen May 09, 2026 · Last updated May 09, 2026
Summary
This study examines the safety and effectiveness of a drug called cemiplimab combined with chemotherapy for people with advanced non-small cell lung cancer. Researchers will look at medical records from about 1,000 patients in the US to see how different groups (by age, sex, race, and ethnicity) respond to this treatment. The goal is to understand real-world outcomes, not to test a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Regeneron Research Facility
Tarrytown, New York, 10591, United States
Conditions
Explore the condition pages connected to this study.